Eli Lilly and Company(LLY)

INDIANAPOLIS, INPharmaceutical2 H-1B visas (FY2023)

Focus: Eli Lilly is a $34.1B revenue Big Pharma company headquartered in Indianapolis, IN with 43,000 employees specializing in biologics discovery across diabetes, oncology, neuroscience, and immunology.

Diabetes Oncology Neuroscience Immunology

Profile data last refreshed 9h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Employees

43,000

Open Jobs

About Eli Lilly and Company

AI assessmentNot Hiring

No open roles listed right now. Follow Eli Lilly and Company to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

6/9 — Partial

Company HealthSolid

Pipeline

Early-stage

50 total

LOE Risk

1 imminent

AXIRON

Hiring

Stable

Revenue

$34.1B

FY2025

Key Products

TRULICITY

Type 2 Diabetes Mellitus

$7.4B

Peak

Company's revenue engine at 59% concentration; GLP-1 agonist in peak commercial phase generating sustained high margins.

Help build intelligence for Eli Lilly and Company

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline & Clinical Trials

LY2503029

Cancer

N/A

Clinical Trials (1)

NCT02632994Master Rollover Protocol for Continued Safety Assessment of Study Drug

N/A

Natural History Study

Sensorineural Hearing Loss, Bilateral

N/A

Clinical Trials (1)

NCT03997981Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY)

N/A

Olaratumab

Soft Tissue Sarcoma

N/A

Clinical Trials (1)

NCT03994627Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma

N/A

Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy

Vestibular Schwannoma

N/A

Propranolol

Healthy

N/A

Clinical Trials (1)

NCT04682184A Study of Continuous Heart Rate Monitoring in Healthy Participants

N/A

Ventriculo-peritonal shunting

Normal Pressure Hydrocephalus

N/A

Clinical Trials (1)

NCT00149721Anterior Pituitary Function in Patients With Hydrocephalus

N/A

Harvard Apparatus syringe pump

Healthy

N/A

Clinical Trials (1)

NCT06516913A Study of Subcutaneous Injection in Healthy Participants

N/A

Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: In

Systemic Autoimmune Diseases

N/A

New Daily Persistent Headache Biomarkers Study

New Daily Persistent Headache

N/A

Clinical Trials (1)

NCT04260087New Daily Persistent Headache Biomarkers Study

N/A

Interview

Caregiver

N/A

Long Term Follow-up Study of AAVAnc80-hOTOF Gene Therapy

Otoferlin Gene-mediated Hearing Loss

N/A

Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases:

Systemic Autoimmune Diseases

N/A

EMC2

Medication Adherence

N/A

Clinical Trials (1)

NCT03652272Development and Evaluation of an Electronic Health Record-based Medication Complete Communication (EMC2) Strategy

N/A

National Register of Actionable Mutations

Solid Tumours in Advanced Stages

N/A

Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Ca

Healthy Subjects

N/A

The Myelin Disorders Biorepository Project

Leukodystrophy

N/A

P-tau217

Subjective Cognitive Impairment

N/A

Clinical Trials (1)

NCT07140744A Study Evaluating the Impact of P-tau217 Blood Biomarker Testing on Early Evaluation and Management of Patients Presenting With Cognitive Complaint

N/A

Follow-up Data of Patients Treated With XIGRIS® in France

Sepsis

N/A

Clinical Trials (1)

NCT00803231Follow-up Data of Patients Treated With XIGRIS® in France

N/A

A Virtual Prospective Study Exploring Activity Trackers and COVID-19 Infections

Covid19

N/A

Genetic Physiopathology and Evolution of Type 2 Diabetes

Pre-Diabetes

N/A

Clinical Trials (1)

NCT00879801Genetic Physiopathology and Evolution of Type 2 Diabetes

N/A

Comprehensive Assessment of Neurodegeneration and Dementia

Dementia

N/A

Clinical Trials (1)

NCT03402919Comprehensive Assessment of Neurodegeneration and Dementia

N/A

Intervention

Depression

N/A

Clinical Trials (1)

NCT01662817Major Depressive Disorder (MDD)

N/A

Glucagon receptor antagonist LY2409021

Diabetes After Total Pancreatectomy

N/A

Clinical Trials (1)

NCT02944110Delineation of the Diabetogenic Role of Extrapancreatic Glucagon in Totally Pancreatectomised Patients Using Glucagon Receptor Antagonism

N/A

Treatment for Fibromyalgia

Fibromyalgia

N/A

Clinical Trials (1)

NCT00725101Fibromyalgia Health Outcome Study on Cost of Treatments

N/A

There are no interventions in this study. All participants complete online surveys.

Lung Cancer Patients

N/A

AM0010

Melanoma

N/A

Clinical Trials (1)

NCT03554434An Expanded Access Program for AM0010 (Pegilodecakin)

N/A

Mirikizumab Real World Protocol

Ulcerative Colitis

N/A

Clinical Trials (1)

NCT06696014Mirikizumab Real World Protocol

N/A

Observational Study of Pergolide Mesylate and Cardiac Valvulopathy

Parkinson Disease

N/A

Clinical Trials (1)

NCT00311532Observational Study of Pergolide Mesylate and Cardiac Valvulopathy

N/A

Fluoxetine

Major Depressive Disorder

N/A

Clinical Trials (1)

NCT00208897Does Fluoxetine Have an Effect on the CNS CRF Systems in Women Abused in Childhood?

N/A

AID System

Type 1 Diabetes Mellitus

N/A

Clinical Trials (1)

NCT03743285A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus (T1D)

N/A

Forteo

Osteoporosis

N/A

Clinical Trials (1)

NCT01155245Teriparatide (PTH) and Bone Strength in Postmenopausal Women

N/A

Retinal scan

Cognitive Dysfunction

N/A

Clinical Trials (1)

NCT07254234A Study of Retinal Imaging to Detect Abnormal Protein Deposits Associated With Alzheimer's Disease

N/A

antipsychotic dose increase

Schizophrenia

N/A

Clinical Trials (1)

NCT00712660Study With Information Technology (IT) - Aided Preventive Program in Schizophrenia

N/A

Duloxetine Hydrochloride

Major Depressive Disorder

N/A

Clinical Trials (1)

NCT00071708Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial

N/A

patient magazine

Osteoporosis

N/A

Clinical Trials (1)

NCT01109472Improving Osteoporosis Care in a Home Health Setting

N/A

exenatide

Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies)

N/A

Celecoxib

Healthy

N/A

Clinical Trials (1)

NCT02413203Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B

N/A

Therapy for head and neck cancer

Head and Neck Cancer

N/A

Clinical Trials (1)

NCT01080313Head and Neck Cancer Registry (LORHAN)

N/A

Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008

Metastatic Breast Cancer

N/A

atomoxetine

Cerebrovascular Accident

N/A

Clinical Trials (1)

NCT00634439Safety Study of Atomoxetine and Cerebrovascular Outcomes

N/A

Teriparatide

Osteoporosis, Postmenopausal

N/A

Clinical Trials (1)

NCT00696644A Study for Teriparatide in Severe Osteoporosis

N/A

rTMS Treatment

Depression

N/A

Clinical Trials (1)

NCT00587639An Evaluation of Safety and Feasibility Using Repetitive Transcranial Magnetic Stimulation (rTMS) in Adolescents With Depression

N/A

Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linag

Diabetes Mellitus, Type 2

N/A

Insulins

Diabetes Mellitus, Type 2

N/A

Clinical Trials (1)

NCT01055808Observational Study in Japanese Type 2 Diabetes Patients

N/A

t:slim X2 insulin pump with Control-IQ technology 1.5

Type 1 Diabetes

N/A

Clinical Trials (1)

NCT05403502Safety Evaluation of an Advanced Hybrid Closed Loop System Using Lyumjev With the Tandem t:Slim X2 Insulin Pump With Control-IQ Technology in Adults, Adolescents and Children With Type 1 Diabetes

N/A

Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Ma

Type 2 Diabetes

N/A

Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2

Chronic Kidney Disease(CKD)

N/A

CBT Based Self-help Workbook + Counseling Telepho

Attention-Deficit/Hyperactivity Disorder

N/A

Clinical Trials (1)

NCT01660464Guided Self-Help for Parents of Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

N/A

Meru Health Program

Depression

N/A

Clinical Trials (1)

NCT05588622Meru Health Program for Cancer Patients With Depression and Anxiety

N/A

Internet based disease management program

Major Depressive Disorder

N/A

Clinical Trials (1)

NCT00485420eCare for Moods: An Internet-based Management Program

N/A

Interview Prep Quick Facts

Portfolio: 164 approved products, 135 clinical trials

Top TAs: Oncology, Metabolic Diseases, Neurology

H-1B (2023): 2 approvals

Publications: 25 in PubMed

SEC Filings: 2 available

Portfolio Health

Pre-Launch36 (22%)

Launch2 (1%)

Growth7 (4%)

Peak20 (12%)

LOE Approaching75 (46%)

Post-LOE24

Therapeutic Area Focus

Oncology

24 marketed698 pipeline

Metabolic Diseases

32 marketed433 pipeline

Neurology

10 marketed250 pipeline

Immunology

13 marketed140 pipeline

Financials (FY2025)

Revenue

$34.1B20%

R&D Spend

$9.3B(27%)30%

Net Income

$5.2B

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Risk Signals

WARN Act Layoff Notices (1)

2024-08-05

— Indianapolis, IN

Source: state DOL filings, aggregated via Big Local News

No active FDA warnings, WARN filings, or reported shortages indicate operational stability; however, patent cliff exposure (2028-2030) and revenue concentration create restructuring risk in medium term.

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Lebrikizumab off-therapy remission sustained up to 38 weeks in atopic dermatitis.

The Journal of dermatological treatment

2026

PMID:41814992

Raising the bar of efficacy in Atopic Dermatitis: deep response in week 16 responders treated with lebrikizumab over 2 years.

Eli Lilly and Company(LLY)

About Eli Lilly and Company

Why Work Here

Key Products

Watch Out For

Products & Portfolio (32)

Key Products by Revenue

Other Products (14)

Pipeline & Clinical Trials

Recent News · Eli Lilly and Company(10)

Open Jobs (0)

Financials (FY2025)

Hiring Trend

Visa Sponsorship

Risk Signals

WARN Act Layoff Notices (1)

Research Publications(10)